Jazz Pharmaceuticals 2026 Third Quarter Earnings - CHIMERIX INC

Explicit Guidance:

• FY2026 Total Revenue: Raised and narrowed to a range of $4.775 billion to $4.85 billion (midpoint ~13% growth vs. 2025); low end of new range exceeds prior high end.
• FY2026 Rare Sleep Revenue: Projected to be $2.125 billion to $2.175 billion, driven by ZYRINE (ZyWave) growth in the low double-digits to low teens.
• FY2026 Non-GAAP Gross Margin: Raised by 50 bps to a range of 90.5% to 91.5%.
• FY2026 Non-GAAP SG&A and R&D Expenses: Guidance unchanged.
• FY2026 Effective Tax Rate: Updated to a range of 19.5% to 21.5% to reflect the non-tax-deductible acquired IPR&D charge from the Actio acquisition.
• FY2026 Share Count: Unchanged at 69 to 70 million shares.

Business-Segment Outlook:

• Zyhera (HER2-positive GEA): Initial net sales were $21M in Q3 2026; peak sales potential updated to a range of $3 billion to $5 billion. Uptake expected to build through 2027 as community integration deepens, with a target population of 3,000–4,000 annual patients in the U.S.
• Medeso (First-line Maintenance Gastric Cancer): Anticipated measured revenue pace in the near term as the commercial focus shifts from academic centers to community settings ahead of Phase 3 ACTiON trial data.
• Zepzelka (SCLC): Expected to face a competitive headwind in 2027 following the anticipated launch of competitor Amgen MDM-2027 (MELTRA) in first-line maintenance; however, no impact on 2026 revenue guidance.
• ZyWave (Narcolepsy/Idiopathic Hypersomnia): Entering 2027 with strong momentum; low-sodium profile and clinical value expected to maintain durability despite introduction of orexin-2 receptor agonists in NT1. High-sodium generic uptake remains limited; payer discussions for 2027 are underway.
• Epidiolex: FDA PDUFA date of April 16, 2027 for a new oral capsule formulation; clinical trials advancing in developmental and epileptic encephalopathies (DEE) and focal onset seizures; long-term patient durability supported into the late 2030s.
• MEDAZO/Zepzelka: MEDAZO achieved $200M in sales since launch; Zepzelka sales up 32% in Q3.

Market and Competitive Outlook:

• Oncology Launch Dynamics: Zyhera launch trajectory driven by new patient starts in community settings (no "washout" from expanded access programs); 80% of new ordering accounts in September were from community clinics.
• Competitive Landscape: Strong new data from Amgen (MELTRA) in first-line extensive-stage SCLC expected to compete with Zepzelka starting in 2027; Jazz expects MELTRA to be approved and reimbursed in the maintenance setting.
• Market Access: Zyhera has secured preferred status in NCCN guidelines (Category 2a) and frictionless formulary adoption; submission made for Category 1 upgrade following final Horizon trial data.
• Testing Rates: Strategic focus on increasing HER2 testing utilization and first-line treatment rates among HER2-positive patients, noting current treatment rates among eligible patients can be as low as 65%.

Macro / Industry Outlook:

• Regulatory Environment: Management expresses optimism regarding FDA's "fit-for-purpose" rare disease framework and support from D.C. policymakers for rare disease innovation (e.g., Globe Medicare Part B pilot exemptions for sole orphan drugs).
• Payer Dynamics: Payer discussions for 2027 are positioned favorably; low-sodium profile of ZyWave and clinical value of Zyhera are highly valued by payers and providers.

Strategic Initiatives:

• Actio Acquisition: Completed acquisition of Actio Biosciences during Q3 2026; asset ABS-1230 (KCNT1 inhibitor) added to pipeline.
• Pipeline Milestones:
  • ABS-1230: Initial patient efficacy data expected to be presented at a medical meeting this quarter; registrational trial (Chiron) progressing.
  • Xanadatamab (Empower-303): Top-line data for metastatic breast cancer expected late 2027 or early 2028.
  • JZP269 (Orexin-2 agonist): Phase I trial initiated in healthy volunteers; potential to target NT1, NT2, and idiopathic hypersomnia.
  • Medeso/ACTiON: Top-line results from the Phase 3 ACTiON trial expected in the first half of 2027.
• Capacity/Operations: Commercial teams actively expanding reach into community oncology settings via peer-to-peer programs and biomarker testing initiatives.

Risks and Headwinds to Outlook:

• Competitive Headwinds: Anticipated launch of MELTRA in 2027 impacting Zepzelka sales in first-line SCLC maintenance.
• Pricing/Payer Risks: Near-term potential extension in time-to-initiation for new patients due to orexin-2 agonist competition in the narcolepsy landscape (NT1).
• Pipeline Uncertainty: Success of future programs (ABS-1230, Xanadatamab, JZP269) dependent on clinical trial results.
• Guidance Caveats: 2026 revenue guidance assumes continued strong execution and minimal impact from high-sodium oxibate generics; excludes one-time charges but includes IPR&D charges.

Management Tone on the Future:

• Confidence Level: Highly confident in the 2026 trajectory and 2027 growth drivers; noted "outstanding execution" allowing for a second consecutive year of raised guidance.
• Strategic Sentiment: Optimistic about the rare disease pipeline (Actio acquisition, FDA support) and the transformative potential of Zyhera across HER2+ cancers.
• Transition: Leadership transition (Sam Pierce retirement) managed to ensure "seamless transition" with the successor appointed.

Miscellaneous:

• Dividends/Buybacks: No specific guidance mentioned regarding dividends or share buybacks; focus on capital allocation for R&D and commercial expansion.
• Cash Position: Finished Q3 2026 with $2.9 billion in cash and investments; operating cash flow of $1.3 billion generated in the first nine months.
• Personnel: Sam Pierce (CCO) retiring; transition support ongoing.